Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens.

Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens.

Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine has been reported in one cohort (C1) of a Phase IIb trial in Mozambique, but waning efficacy was observed in a smaller contemporaneous cohort (C2). We hypothesized that low dose exposure to asexual s...

Full description

Bibliographic Details
Main Authors:	Joseph J Campo, Carlota Dobaño, Jahit Sacarlal, Caterina Guinovart, Alfredo Mayor, Evelina Angov, Sheetij Dutta, Chetan Chitnis, Eusebio Macete, John J Aponte, Pedro L Alonso
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3192128?pdf=render

Similar Items

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.
by: Caterina Guinovart, et al.
Published: (2009-01-01)

Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure
by: Liriye Kurtovic, et al.
Published: (2019-02-01)

Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
by: Gaoqian Feng, et al.
Published: (2022-08-01)

Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure.
by: Gemma Moncunill, et al.
Published: (2013-01-01)

Analysis of factors affecting the variability of a quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens.
by: Itziar Ubillos, et al.
Published: (2018-01-01)

Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
by: Lina Sánchez, et al.
Published: (2022-08-01)

Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response [version 2; referees: 2 approved]
by: Darawan Rinchai, et al.
Published: (2017-07-01)

Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial
by: Mandomando Inacio, et al.
Published: (2007-03-01)

Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
by: Itziar Ubillos, et al.
Published: (2018-10-01)

RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study
by: Carlota Dobaño, et al.
Published: (2019-08-01)

Malaria in rural Mozambique. Part II: children admitted to hospital
by: Macete Eusébio, et al.
Published: (2008-02-01)

Malaria in rural Mozambique. Part I: Children attending the outpatient clinic
by: Macete Eusébio, et al.
Published: (2008-02-01)

Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis
by: Sidhartha Chaudhury, et al.
Published: (2017-08-01)

Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study
by: Gemma Moncunill, et al.
Published: (2022-01-01)

High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria.
by: Gemma Moncunill, et al.
Published: (2013-01-01)

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
by: Agnandji, S, et al.
Published: (2012)

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.
by: Bejon, P, et al.
Published: (2011)

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
by: Vekemans Johan, et al.
Published: (2011-08-01)

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
by: Agnandji, S, et al.
Published: (2011)

The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
by: Caterina Guinovart, et al.
Published: (2012-01-01)

Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivax
by: Mayara B Barbedo, et al.
Published: (2007-06-01)

Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model
by: Christopher J. Genito, et al.
Published: (2023-08-01)

Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications
by: Sanz Sergi, et al.
Published: (2007-09-01)

Effect of RTS,S/AS01E vaccine booster dose on cellular immune responses in African infants and children
by: Robert A. Mitchell, et al.
Published: (2024-10-01)

RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial
by: Gemma Moncunill, et al.
Published: (2017-08-01)

Correction: Randomized Controlled Trial of RTS,S/AS02 and RTS,S/AS01 Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children.
by: Seth Owusu-Agyei, et al.
Published: (2010-01-01)

T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.
by: Daniel Ansong, et al.
Published: (2011-04-01)

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
by: Seth Owusu-Agyei, et al.
Published: (2009-10-01)

Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
by: Pedro Aide, et al.
Published: (2010-11-01)

Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine
by: Philippe Moris, et al.
Published: (2018-01-01)

IgM and IgG against Plasmodium falciparum lysate as surrogates of malaria exposure and protection during pregnancy
by: Alfredo Mayor, et al.
Published: (2018-05-01)

THE RTS,S MALARIA VACCINE What is the efficacy of the RTS,S malaria vaccine?
by: Duncan, C, et al.
Published: (2011)

Correction: Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
Published: (2010-01-01)

Estimated Burden of Serious Fungal Infections in Mozambique
by: Jahit Sacarlal, et al.
Published: (2018-06-01)

Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy
by: Carlota Dobaño, et al.
Published: (2019-05-01)

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.
by: Vekemans, J, et al.
Published: (2011)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
by: Juliette Fortpied, et al.
Published: (2020-06-01)

Reduced Placental Transfer of Antibodies Against a Wide Range of Microbial and Vaccine Antigens in HIV-Infected Women in Mozambique
by: Selena Alonso, et al.
Published: (2021-03-01)

RTS,S: the first malaria vaccine
by: Fidel Zavala
Published: (2022-01-01)

Activation Energy of RTS Noise
by: J. Pavelka, et al.
Published: (2011-04-01)